Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total assets | 70,773 | 71,294 | 69,867 | 62,894 | 51,293 |
| Current assets | 49,608 | 52,044 | 51,490 | 46,760 | 35,970 |
| Cash and equivalents | 38,734 | 40,527 | 40,955 | 36,122 | 24,086 |
| Short-term investments | 107 | 109 | 114 | 109 | 110 |
| Inventory | 2,994 | 2,886 | 2,878 | 2,581 | 2,401 |
| Net property, plant and equipment | 8,455 | 8,128 | 7,908 | 7,231 | 7,085 |
| Other intangible assets | 7,963 | 7,421 | 6,834 | 5,768 | 5,321 |
| Long-term investments | 801 | 529 | 557 | 625 | 642 |
| Current liabilities | 4,247 | 5,637 | 6,369 | 3,465 | 3,363 |
| Accounts payable | 2,029 | 2,335 | 2,270 | 2,199 | 1,997 |
| Total debt | 68.0 | 67.5 | 74.2 | 91.4 | 109 |
| Total liabilities | 5,783 | 7,147 | 8,070 | 3,864 | 3,743 |
| Total equity (incl. minority) | 64,990 | 64,147 | 61,797 | 59,030 | 47,550 |
| Retained earnings | 43,313 | 42,456 | 40,173 | 37,042 | 35,740 |
| Minority interest | 523 | 521 | 525 | 565 | 563 |